Clinical Trials
23 trialsNCT07378098 2026-05-01
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
JW Pharmaceutical
Phase 3 Recruiting
NCT06671548 2026-02-02
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03271489 2025-07-22
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 3 Completed
NCT03751124 2024-06-25
Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03412890 2024-05-09
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03400943 2023-05-03
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
Bayer
Phase 3 Terminated
NCT05620355 2023-03-21
Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.
Bio Genuine (Shanghai) Biotech Co., Ltd.
Phase 3 Unknown
NCT03476928 2022-07-08
ASTEROID 8
Bayer
Phase 3 Terminated
NCT03400956 2022-06-30
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
Bayer
Phase 3 Terminated
NCT03103087 2022-04-20
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT03049735 2022-04-19
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Myovant Sciences GmbH
Phase 3 Completed
NCT02691494 2021-07-13
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)
AbbVie
Phase 3 Completed
NCT02925494 2021-07-13
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
AbbVie
Phase 3 Completed
NCT03070899 2021-06-09
PRIMROSE 1
ObsEva SA
Phase 3 Completed
NCT03070951 2021-03-05
PRIMROSE 2
ObsEva SA
Phase 3 Completed
NCT02654054 2020-06-29
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 3 Completed
NCT00152256 2008-05-29
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids
Abbott
Phase 3 Completed
NCT00152269 2008-05-29
Treatment of Uterine Fibroids With Asoprisnil(J867)
Abbott
Phase 3 Completed
NCT00156195 2008-05-29
Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids
Abbott
Phase 3 Completed
NCT00156208 2008-05-29
Safety of Treatment of Uterine Fibroids With Asoprisnil
Abbott
Phase 3 Completed
NCT00160381 2008-05-29
A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids
Abbott
Phase 3 Completed
NCT00156156 2008-05-28
Study of Asoprisnil in the Treatment of Uterine Fibroids.
Abbott
Phase 3 Completed
NCT00100191 2005-06-24
Emmy Trial: Uterine Artery Embolization (UAE) Versus Hysterectomy for Uterine Fibroids
ZonMw: The Netherlands Organisation for Health Research and Development
Phase 3 Completed